MX367647B - Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a. - Google Patents

Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a.

Info

Publication number
MX367647B
MX367647B MX2016015180A MX2016015180A MX367647B MX 367647 B MX367647 B MX 367647B MX 2016015180 A MX2016015180 A MX 2016015180A MX 2016015180 A MX2016015180 A MX 2016015180A MX 367647 B MX367647 B MX 367647B
Authority
MX
Mexico
Prior art keywords
phosphodiesterase
inhibitors
triazole derivatives
fused triazole
compounds
Prior art date
Application number
MX2016015180A
Other languages
English (en)
Other versions
MX2016015180A (es
Inventor
BOJARSKI Lukasz
Wieczorek Maciej
MAJER Jakub
JANOWSKA Sylwia
MATLOKA Mikolaj
Borkowska Malgorzata
Stefaniak Filip
Lamparska-Przybysz Monika
DUBIEL Krzysztof
Moszczynski-Petkowski Rafal
Original Assignee
Celon Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Sa filed Critical Celon Pharma Sa
Publication of MX2016015180A publication Critical patent/MX2016015180A/es
Publication of MX367647B publication Critical patent/MX367647B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Lubricants (AREA)

Abstract

Compuestos de la fórmula general (I), en donde una de X1 y X2 representa N, y la otra de X1 y X2 representa -C(CH3), A representa arilo o heteroarilo de 5, 6 ó 10 miembros no sustituido o sustituido, n es 0 ó 1 y B es un hetero-radical bicíclico definido en la especificación; los compuestos son inhibidores de fosfodiesterasa 10A y pueden encontrar uso en medicina en el tratamiento de enfermedades y trastornos de las funciones psicótica, neurológica y cognitiva. (ver Fórmula).
MX2016015180A 2014-05-19 2015-05-14 Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a. MX367647B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PL408251A PL408251A1 (pl) 2014-05-19 2014-05-19 Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A
PCT/IB2015/053549 WO2015177688A1 (en) 2014-05-19 2015-05-14 Fused triazole derivatives as phosphodiesterase 10a inhibitors

Publications (2)

Publication Number Publication Date
MX2016015180A MX2016015180A (es) 2017-03-23
MX367647B true MX367647B (es) 2019-08-29

Family

ID=53434395

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015180A MX367647B (es) 2014-05-19 2015-05-14 Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a.

Country Status (17)

Country Link
US (1) US10138245B2 (es)
EP (1) EP3145930B1 (es)
JP (1) JP6455947B2 (es)
KR (1) KR102404650B1 (es)
CN (1) CN106459060B (es)
AU (1) AU2015263013B2 (es)
CA (1) CA2946258C (es)
DK (1) DK3145930T3 (es)
EA (1) EA030330B9 (es)
ES (1) ES2688084T3 (es)
HR (1) HRP20181027T1 (es)
HU (1) HUE039847T2 (es)
MX (1) MX367647B (es)
PL (2) PL408251A1 (es)
PT (1) PT3145930T (es)
SI (1) SI3145930T1 (es)
WO (1) WO2015177688A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017007301A1 (en) * 2015-07-06 2017-01-12 Universiti Sains Malaysia Compound and method for inhibiting sirtuin activities
KR102587382B1 (ko) * 2016-04-29 2023-10-12 솔루스첨단소재 주식회사 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자
CN111410657B (zh) * 2019-01-08 2024-05-21 北京鼎材科技有限公司 一种发光材料及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009011893A2 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
TWI501965B (zh) * 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
US8410117B2 (en) 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
US8975276B2 (en) * 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10

Also Published As

Publication number Publication date
AU2015263013A1 (en) 2016-11-17
PL3145930T3 (pl) 2018-11-30
US20170114064A1 (en) 2017-04-27
US10138245B2 (en) 2018-11-27
WO2015177688A1 (en) 2015-11-26
EA030330B1 (ru) 2018-07-31
EP3145930A1 (en) 2017-03-29
PL408251A1 (pl) 2015-11-23
ES2688084T3 (es) 2018-10-30
EA030330B9 (ru) 2018-09-28
PT3145930T (pt) 2018-10-11
EA201692264A1 (ru) 2017-04-28
CN106459060A (zh) 2017-02-22
JP2017521364A (ja) 2017-08-03
CA2946258C (en) 2023-06-06
MX2016015180A (es) 2017-03-23
KR20170005860A (ko) 2017-01-16
CN106459060B (zh) 2019-04-05
AU2015263013B2 (en) 2018-10-04
SI3145930T1 (sl) 2018-10-30
HUE039847T2 (hu) 2019-02-28
CA2946258A1 (en) 2015-11-26
JP6455947B2 (ja) 2019-01-23
DK3145930T3 (en) 2018-09-24
HRP20181027T1 (hr) 2018-08-24
KR102404650B1 (ko) 2022-06-02
EP3145930B1 (en) 2018-07-04

Similar Documents

Publication Publication Date Title
TR201904658T4 (tr) Bisiklik füzyonla birleştirilmiş heteroaril veya aril bileşikleri ve bunların ırak4 inhibitörleri olarak kullanımları.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
CL2018000338A1 (es) Derivados de heteroarilo como inhiidores de parp
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790271A1 (ru) Ингибиторы гликозидазы
MX2016015532A (es) Esteroides neuroactivos, composiciones, y usos de los mismos.
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
EA201691447A1 (ru) 2-амино-3,5,5-трифтор-3,4,5,6-тетрагидропиридины в качестве ингибиторов bace1 для лечения болезни альцгеймера
EA201891526A3 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2016015180A (es) Derivados de triazol fusionados como inhibidores de fosfodiesterasa 10a.
NZ732511A (en) Small molecule inhibitors of egfr and pi3k
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
EA201990400A1 (ru) Соединения и композиции и их применение
MY174747A (en) Bace1 inhibitors
CL2017000006A1 (es) Derivados de quinolizinona como inhibidores de pi3k
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
CA2887539C (en) Azaquinazoline carboxamide derivatives
SG10201900954SA (en) Heterocycles as Modulators of Kinase Activity
NZ631388A (en) Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
EA201692227A1 (ru) Производные сложных аминоэфиров

Legal Events

Date Code Title Description
FG Grant or registration